News

Shionogi will use the Qumas technology for users across the clinical and quality assurance areas to control standard operating procedures, policies and manuals, based on the global regulatory

The breakthrough therapy designation was based on preliminary Phase 2 trial, which demonstrated that women treated with the combination of palbociclib plus letrozole achieved a statistically significant improvement

Myrbetriq is indicated to treat OAB with symptoms of urge urinary incontinence, urgency and urinary frequency. The University of Western Ontario urology adjunct professor, St. Mary’s General Hospital

Concentrations of up to 24 micromolar of Adva-27a did not appreciably inhibit the normal growth process of the cells. Sunshine Biopharma CEO Dr. Steve Slilaty said the data

As part of the agreement, Inventiva and NovAliX offer pharmaceutical and biotech companies a set of fully integrated nuclear receptor drug discovery capabilities. The collaboration will use both

Ranibizumab is used to treat people with visual impairment due to macular oedema secondary to Retinal Vein Occlusion (RVO). The positive NICE Final Appraisal Determination (FAD) has recommended

Ergomed has been selected as the contract clinical development organization to conduct the Phase 3 trial with AEZS-108 in endometrial cancer. As per the agreement, Ergomed will assume

New facility for Bio-Manguinhos will use iBio’s plant-based protein expression technology, iBioLaunch, and GE Healthcare’s expertise in process design and start-to-finish biopharmaceutical and vaccine manufacturing technologies. GE Healthcare

As per the agreement, Shasun Pharmaceuticals will use the Debiopharm technology for the manufacture of synthetic Huperzine-A under GMP quality conditions and commercialize it in pharmaceutical and nutraceutical